NLSP Projected Dividend Yield

Ord/NLS Pharmaceutics Ltd ( NASDAQ : NLSP )

NLS Pharmaceutics is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system disorders with unmet medical needs. Co.'s main compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary controlled release formulation, is being developed for the treatment of narcolepsy and attention deficit hyperactivity disorder (ADHD). Co.'s focus includes its primary product candidate: Quilience, for the treatment of excessive daytime sleepiness and cataplexy associated with narcolepsy, and Nolazol, for the treatment of ADHD.

20 YEAR PERFORMANCE RESULTS